Effect of PKK and fXII ASO treatment on PKK and fXII hepatic mRNA and plasma protein levels. Male BALB/c mice were treated subcutaneously with PKK or fXII ASO for 3 weeks at indicated doses (n = 8 per treatment group). Two days after final dosing mice were collected for quantification of PKK and fXII hepatic mRNA levels (A) and PKK and fXII immunoblot analysis on pooled (B) and individual (C-D) samples. PKK and fXII relative plasma protein levels were quantified by densitometry. *P ≤ .05, **P ≤ .01 and ***P ≤ .001 compared with untreated control.